Psychopharmacology  ||| S:0 E:19 ||| NNP
of  ||| S:19 E:22 ||| IN
depression  ||| S:22 E:33 ||| NN
and  ||| S:33 E:37 ||| CC
sexual  ||| S:37 E:44 ||| JJ
disorders  ||| S:44 E:54 ||| NNS
Sexual  ||| S:54 E:61 ||| JJ
dysfunctions  ||| S:61 E:74 ||| NN
as  ||| S:74 E:77 ||| IN
side  ||| S:77 E:82 ||| NN
effects  ||| S:82 E:90 ||| NNS
of  ||| S:90 E:93 ||| IN
antidepressant  ||| S:93 E:108 ||| JJ
treatments  ||| S:108 E:119 ||| NNS
are  ||| S:119 E:123 ||| VBP
being  ||| S:123 E:129 ||| VBG
reported  ||| S:129 E:138 ||| VBN
more  ||| S:138 E:143 ||| RBR
and  ||| S:143 E:147 ||| CC
more  ||| S:147 E:152 ||| RBR
frequently ||| S:152 E:162 ||| RB
:  ||| S:162 E:164 ||| :
they  ||| S:164 E:169 ||| PRP
are  ||| S:169 E:173 ||| VBP
one  ||| S:173 E:177 ||| CD
of  ||| S:177 E:180 ||| IN
the  ||| S:180 E:184 ||| DT
main  ||| S:184 E:189 ||| JJ
reasons  ||| S:189 E:197 ||| NNS
of  ||| S:197 E:200 ||| IN
dropout  ||| S:200 E:208 ||| NN
from  ||| S:208 E:213 ||| IN
therapy ||| S:213 E:220 ||| NN
.  ||| S:220 E:222 ||| .
These  ||| S:222 E:228 ||| DT
side  ||| S:228 E:233 ||| NN
effects  ||| S:233 E:241 ||| NNS
are  ||| S:241 E:245 ||| VBP
reported  ||| S:245 E:254 ||| VBN
in  ||| S:254 E:257 ||| IN
between  ||| S:257 E:265 ||| IN
20 ||| S:265 E:267 ||| CD
%  ||| S:267 E:269 ||| NN
and  ||| S:269 E:273 ||| CC
40 ||| S:273 E:275 ||| CD
%  ||| S:275 E:277 ||| NN
of  ||| S:277 E:280 ||| IN
cases ||| S:280 E:285 ||| NNS
.  ||| S:285 E:287 ||| .
The  ||| S:287 E:291 ||| DT
aim  ||| S:291 E:295 ||| NN
of  ||| S:295 E:298 ||| IN
this  ||| S:298 E:303 ||| DT
study  ||| S:303 E:309 ||| NN
is  ||| S:309 E:312 ||| VBZ
to  ||| S:312 E:315 ||| TO
highlight ||| S:315 E:324 ||| VB
,  ||| S:324 E:326 ||| ,
following  ||| S:326 E:336 ||| VBG
the  ||| S:336 E:340 ||| DT
actual  ||| S:340 E:347 ||| JJ
evidence  ||| S:347 E:356 ||| NN
from  ||| S:356 E:361 ||| IN
the  ||| S:361 E:365 ||| DT
field  ||| S:365 E:371 ||| NN
of  ||| S:371 E:374 ||| IN
psychopharmacology ||| S:374 E:392 ||| NN
,  ||| S:392 E:394 ||| ,
how  ||| S:394 E:398 ||| WRB
these  ||| S:398 E:404 ||| DT
side  ||| S:404 E:409 ||| NN
effects  ||| S:409 E:417 ||| NNS
may  ||| S:417 E:421 ||| MD
not  ||| S:421 E:425 ||| RB
be  ||| S:425 E:428 ||| VB
directly  ||| S:428 E:437 ||| RB
related  ||| S:437 E:445 ||| VBN
to  ||| S:445 E:448 ||| TO
the  ||| S:448 E:452 ||| DT
antidepressant  ||| S:452 E:467 ||| JJ
treatment ||| S:467 E:476 ||| NN
;  ||| S:476 E:478 ||| :
on  ||| S:478 E:481 ||| IN
the  ||| S:481 E:485 ||| DT
contrary  ||| S:485 E:494 ||| NN
we  ||| S:494 E:497 ||| PRP
show  ||| S:497 E:502 ||| VBP
that ||| S:502 E:506 ||| RB
,  ||| S:506 E:508 ||| ,
following  ||| S:508 E:518 ||| VBG
the  ||| S:518 E:522 ||| DT
observational  ||| S:522 E:536 ||| JJ
clinical  ||| S:536 E:545 ||| JJ
data  ||| S:545 E:550 ||| NNS
obtained  ||| S:550 E:559 ||| VBN
in  ||| S:559 E:562 ||| IN
our  ||| S:562 E:566 ||| PRP$
Mental  ||| S:566 E:573 ||| NNP
Health  ||| S:573 E:580 ||| NNP
Dept. ||| S:580 E:585 ||| NNP
,  ||| S:585 E:587 ||| ,
a  ||| S:587 E:589 ||| DT
careful  ||| S:589 E:597 ||| JJ
clinical  ||| S:597 E:606 ||| JJ
interview  ||| S:606 E:616 ||| NN
about  ||| S:616 E:622 ||| IN
the  ||| S:622 E:626 ||| DT
sexual  ||| S:626 E:633 ||| JJ
behaviour  ||| S:633 E:643 ||| NN
of  ||| S:643 E:646 ||| IN
the  ||| S:646 E:650 ||| DT
patients  ||| S:650 E:659 ||| NNS
allows  ||| S:659 E:666 ||| VBZ
psychotherapy  ||| S:666 E:680 ||| VBN
to  ||| S:680 E:683 ||| TO
interact  ||| S:683 E:692 ||| VB
with  ||| S:692 E:697 ||| IN
pharmacotherapy ||| S:697 E:712 ||| NN
,  ||| S:712 E:714 ||| ,
in  ||| S:714 E:717 ||| IN
order  ||| S:717 E:723 ||| NN
to  ||| S:723 E:726 ||| TO
reduce  ||| S:726 E:733 ||| VB
the  ||| S:733 E:737 ||| DT
drug  ||| S:737 E:742 ||| NN
dosage ||| S:742 E:748 ||| NN
,  ||| S:748 E:750 ||| ,
or  ||| S:750 E:753 ||| CC
replace  ||| S:753 E:761 ||| VB
it  ||| S:761 E:764 ||| PRP
with  ||| S:764 E:769 ||| IN
another  ||| S:769 E:777 ||| DT
drug ||| S:777 E:781 ||| NN
,  ||| S:781 E:783 ||| ,
and ||| S:783 E:786 ||| CC
/ ||| S:786 E:787 ||| NNP
or  ||| S:787 E:790 ||| CC
to  ||| S:790 E:793 ||| TO
combine  ||| S:793 E:801 ||| VB
an  ||| S:801 E:804 ||| DT
erectile  ||| S:804 E:813 ||| JJ
dysfunction  ||| S:813 E:825 ||| JJ
treatment  ||| S:825 E:835 ||| NN
with  ||| S:835 E:840 ||| IN
the  ||| S:840 E:844 ||| DT
psychopharmacological  ||| S:844 E:866 ||| JJ
therapy ||| S:866 E:873 ||| NN
.  ||| S:873 E:875 ||| .
This  ||| S:875 E:880 ||| DT
careful  ||| S:880 E:888 ||| JJ
clinical  ||| S:888 E:897 ||| JJ
interview  ||| S:897 E:907 ||| NN
about  ||| S:907 E:913 ||| IN
the  ||| S:913 E:917 ||| DT
sexual  ||| S:917 E:924 ||| JJ
behavior  ||| S:924 E:933 ||| NN
of  ||| S:933 E:936 ||| IN
the  ||| S:936 E:940 ||| DT
patients  ||| S:940 E:949 ||| NNS
will  ||| S:949 E:954 ||| MD
more  ||| S:954 E:959 ||| RBR
clearly  ||| S:959 E:967 ||| RB
determine  ||| S:967 E:977 ||| VB
the  ||| S:977 E:981 ||| DT
percentages  ||| S:981 E:993 ||| NNS
of  ||| S:993 E:996 ||| IN
sexual  ||| S:996 E:1003 ||| JJ
dysfunction  ||| S:1003 E:1015 ||| JJ
side  ||| S:1015 E:1020 ||| NN
effects ||| S:1020 E:1027 ||| NNS
,  ||| S:1027 E:1029 ||| ,
and  ||| S:1029 E:1033 ||| CC
also  ||| S:1033 E:1038 ||| RB
avoid  ||| S:1038 E:1044 ||| VB
drop-out  ||| S:1044 E:1053 ||| JJ
from  ||| S:1053 E:1058 ||| IN
antidepressant  ||| S:1058 E:1073 ||| JJ
therapy ||| S:1073 E:1080 ||| NN
.  ||| S:1080 E:1082 ||| .
